Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Corey Langer

Showing results (1-10 of 101) with videos related to

Pageof 11
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|November 11, 2005
Management of bone metastases: 2005 updateCorey Langer
Seminars in Oncology|December 16, 2004
Role of chemotherapy in patients with poor performance status and advanced non-small cell lung cancerCorey Langer, Rogerio Lilenbaum
Seminars in Respiratory and Critical Care Medicine|November 22, 2013
Treatment of lung cancer in the elderly patientJared Weiss, Corey Langer
The Lancet. Oncology|December 1, 2023
Tumor Treating Fields therapy in metastatic non-small-cell lung cancer - Authors' replyTiciana Leal, Corey Langer
Lung Cancer (Amsterdam, Netherlands)|November 27, 2009
Skeletal morbidity in lung cancer patients with bone metastases: demonstrating the need for early diagnosis and treatment with bisphosphonatesCorey Langer, Vera Hirsh
Seminars in Oncology|December 16, 2004
Patients with non-small cell lung cancer and poor performance status: a significant population with limited dataCorey Langer, Rogerio Lilenbaum
Current Opinion in Oncology|February 28, 2008
The changing landscape of the medical management of skeletal metastases in nonsmall cell lung cancerJohn Kosteva, Corey Langer
Current Treatment Options in Oncology|May 19, 2009
NSCLC in the elderly--the legacy of therapeutic neglectJared Weiss, Corey Langer
Lung Cancer (Amsterdam, Netherlands)|December 14, 2002
First-line chemotherapy for NSCLC: an overview of relevant trialsChandra P Belani, Corey Langer,
Clinical Lung Cancer|March 5, 2010
The role of anti-epidermal growth factor receptor and anti-vascular endothelial growth factor therapies in the treatment of non-small-cell lung cancerCorey Langer, Jean-Charles Soria
Pageof 11

Showing results (1-10 of 101) with videos related to

Sort By:
Pageof 11
Journal of the National Comprehensive Cancer Network : JNCCN|November 11, 2005
Management of bone metastases: 2005 updateCorey Langer
Seminars in Oncology|December 16, 2004
Role of chemotherapy in patients with poor performance status and advanced non-small cell lung cancerCorey Langer, Rogerio Lilenbaum
Seminars in Respiratory and Critical Care Medicine|November 22, 2013
Treatment of lung cancer in the elderly patientJared Weiss, Corey Langer
The Lancet. Oncology|December 1, 2023
Tumor Treating Fields therapy in metastatic non-small-cell lung cancer - Authors' replyTiciana Leal, Corey Langer
Lung Cancer (Amsterdam, Netherlands)|November 27, 2009
Skeletal morbidity in lung cancer patients with bone metastases: demonstrating the need for early diagnosis and treatment with bisphosphonatesCorey Langer, Vera Hirsh
Seminars in Oncology|December 16, 2004
Patients with non-small cell lung cancer and poor performance status: a significant population with limited dataCorey Langer, Rogerio Lilenbaum
Current Opinion in Oncology|February 28, 2008
The changing landscape of the medical management of skeletal metastases in nonsmall cell lung cancerJohn Kosteva, Corey Langer
Current Treatment Options in Oncology|May 19, 2009
NSCLC in the elderly--the legacy of therapeutic neglectJared Weiss, Corey Langer
Lung Cancer (Amsterdam, Netherlands)|December 14, 2002
First-line chemotherapy for NSCLC: an overview of relevant trialsChandra P Belani, Corey Langer,
Clinical Lung Cancer|March 5, 2010
The role of anti-epidermal growth factor receptor and anti-vascular endothelial growth factor therapies in the treatment of non-small-cell lung cancerCorey Langer, Jean-Charles Soria
Pageof 11